OncotypeDX Testing Does Not Benefit Patients with Estrogen and Progesterone Receptor Positive Grade 1 Breast Cancers: A TAILORx Validated Study.

Udai S Sibia,Charles Mylander,Tasha Martin,Martin Rosman,Thomas J Sanders,Young Lee,Lorraine Tafra,Rubie S Jackson

Hematology/oncology and stem cell therapy（2023）

引用 0|浏览2

暂无评分

摘要

OncotypeDX testing does not benefit AAMC low-risk patients with hormone-positive grade 1 tumors. Based on these data, 1 in 4 TAILORx participants would not need OncotypeDX testing.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要